Literature DB >> 22325097

AP-2β regulates amyloid beta-protein stimulation of apolipoprotein E transcription in astrocytes.

Ximena S Rossello1, Urule Igbavboa, Gary A Weisman, Grace Y Sun, W Gibson Wood.   

Abstract

Two key players involved in Alzheimer's disease (AD) are amyloid beta protein (Aβ) and apolipoprotein E (apoE). Aβ increases apoE protein levels in astrocytes which is associated with cholesterol trafficking, neuroinflammatory responses and Aβ clearance. The mechanism for the increase in apoE protein abundance is not understood. Based on different lines of evidence, we propose that the beta-adrenergic receptor (βAR), cAMP and the transcription factor activator protein-2 (AP-2) are contributors to the Aβ-induced increase in apoE abundance. This hypothesis was tested in mouse primary astrocytes and in cells transfected with an apoE promoter fragment with binding sites for AP-2. Aβ(42) induced a time-dependent increase in apoE mRNA and protein levels which were significantly inhibited by βAR antagonists. A novel finding was that Aβ incubation significantly reduced AP-2α levels and significantly increased AP-2β levels in the nuclear fraction. The impact of Aβ-induced translocation of AP-2 into the nucleus was demonstrated in cells expressing AP-2 and incubated with Aβ(42). AP-2 expressing cells had enhanced activation of the apoE promoter region containing AP-2 binding sites in contrast to AP-2 deficient cells. The transcriptional upregulation of apoE expression by Aβ(42) may be a neuroprotective response to Aβ-induced cytotoxicity, consistent with apoE's role in cytoprotection.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22325097      PMCID: PMC3292686          DOI: 10.1016/j.brainres.2012.01.017

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  54 in total

1.  Apolipoprotein E and peptide mimetics modulate inflammation by binding the SET protein and activating protein phosphatase 2A.

Authors:  Dale J Christensen; Nobutaka Ohkubo; Jessica Oddo; Michael J Van Kanegan; Jessica Neil; Fengqiao Li; Carol A Colton; Michael P Vitek
Journal:  J Immunol       Date:  2011-02-15       Impact factor: 5.422

2.  Important differences between human and mouse APOE gene promoters: limitation of mouse APOE model in studying Alzheimer's disease.

Authors:  Bryan Maloney; Yuan-Wen Ge; George M Alley; Debomoy K Lahiri
Journal:  J Neurochem       Date:  2007-09-08       Impact factor: 5.372

Review 3.  Astrocytic beta(2)-adrenergic receptors: from physiology to pathology.

Authors:  Guy Laureys; Ralph Clinckers; Sarah Gerlo; Anneleen Spooren; Nadine Wilczak; Ron Kooijman; Ilse Smolders; Yvette Michotte; Jacques De Keyser
Journal:  Prog Neurobiol       Date:  2010-02-04       Impact factor: 11.685

4.  An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia.

Authors:  Jianjia Fan; Sophie Stukas; Charmaine Wong; Jennifer Chan; Sharon May; Nicole DeValle; Veronica Hirsch-Reinshagen; Anna Wilkinson; Michael N Oda; Cheryl L Wellington
Journal:  J Lipid Res       Date:  2011-06-26       Impact factor: 5.922

5.  Binding of amyloid beta peptide to beta2 adrenergic receptor induces PKA-dependent AMPA receptor hyperactivity.

Authors:  Dayong Wang; G Govindaiah; Ruijie Liu; Vania De Arcangelis; Charles L Cox; Yang K Xiang
Journal:  FASEB J       Date:  2010-04-15       Impact factor: 5.191

6.  An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury.

Authors:  Feng-Qiao Li; Kenneth A Fowler; Jessica E Neil; Carol A Colton; Michael P Vitek
Journal:  J Pharmacol Exp Ther       Date:  2010-04-20       Impact factor: 4.030

7.  Shift in AP-2alpha localization characterizes astrocytoma progression.

Authors:  Ramona Britto; S Umesh; A S Hegde; Sridevi Hegde; Vani Santosh; B A Chandramouli; Kumaravel Somasundaram
Journal:  Cancer Biol Ther       Date:  2007-03-28       Impact factor: 4.742

8.  Amyloid beta-protein stimulates trafficking of cholesterol and caveolin-1 from the plasma membrane to the Golgi complex in mouse primary astrocytes.

Authors:  U Igbavboa; G Y Sun; G A Weisman; Yan He; W G Wood
Journal:  Neuroscience       Date:  2009-05-03       Impact factor: 3.590

9.  apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain.

Authors:  Rashid Deane; Abhay Sagare; Katie Hamm; Margaret Parisi; Steven Lane; Mary Beth Finn; David M Holtzman; Berislav V Zlokovic
Journal:  J Clin Invest       Date:  2008-11-13       Impact factor: 14.808

Review 10.  Greasing the wheels of Abeta clearance in Alzheimer's disease: the role of lipids and apolipoprotein E.

Authors:  Jianjia Fan; James Donkin; Cheryl Wellington
Journal:  Biofactors       Date:  2009 May-Jun       Impact factor: 6.113

View more
  12 in total

1.  High-density lipoprotein mimetic peptide 4F mitigates amyloid-β-induced inhibition of apolipoprotein E secretion and lipidation in primary astrocytes and microglia.

Authors:  Dustin Chernick; Stephanie Ortiz-Valle; Angela Jeong; Suresh K Swaminathan; Karunya K Kandimalla; G William Rebeck; Ling Li
Journal:  J Neurochem       Date:  2018-11-26       Impact factor: 5.372

Review 2.  Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis.

Authors:  W Gibson Wood; Ling Li; Walter E Müller; Gunter P Eckert
Journal:  J Neurochem       Date:  2014-01-02       Impact factor: 5.372

Review 3.  Molecular approaches for manipulating astrocytic signaling in vivo.

Authors:  Alison X Xie; Jeremy Petravicz; Ken D McCarthy
Journal:  Front Cell Neurosci       Date:  2015-04-21       Impact factor: 5.505

Review 4.  Neuroinflammation in Alzheimer's disease.

Authors:  Fengjin Zhang; Linlan Jiang
Journal:  Neuropsychiatr Dis Treat       Date:  2015-01-30       Impact factor: 2.570

5.  RXR controlled regulatory networks identified in mouse brain counteract deleterious effects of Aβ oligomers.

Authors:  Kyong Nyon Nam; Anais Mounier; Nicholas F Fitz; Cody Wolfe; Jonathan Schug; Iliya Lefterov; Radosveta Koldamova
Journal:  Sci Rep       Date:  2016-04-07       Impact factor: 4.379

6.  Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer's Disease Mouse Model.

Authors:  Wan Nurzulaikha Wan Nasri; Suzana Makpol; Musalmah Mazlan; Ikuo Tooyama; Wan Zurinah Wan Ngah; Hanafi Ahmad Damanhuri
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

7.  Amyloid β inhibits retinoic acid synthesis exacerbating Alzheimer disease pathology which can be attenuated by an retinoic acid receptor α agonist.

Authors:  Maria B Goncalves; Earl Clarke; Carl Hobbs; Tony Malmqvist; Robert Deacon; Julian Jack; Jonathan P T Corcoran
Journal:  Eur J Neurosci       Date:  2013-02-04       Impact factor: 3.386

Review 8.  Transcriptional regulation and its misregulation in Alzheimer's disease.

Authors:  Xiao-Fen Chen; Yun-wu Zhang; Huaxi Xu; Guojun Bu
Journal:  Mol Brain       Date:  2013-10-21       Impact factor: 4.041

9.  Inhibition of APE1/Ref-1 redox activity rescues human retinal pigment epithelial cells from oxidative stress and reduces choroidal neovascularization.

Authors:  Y Li; X Liu; T Zhou; M R Kelley; P Edwards; H Gao; X Qiao
Journal:  Redox Biol       Date:  2014-02-21       Impact factor: 11.799

10.  Mechanisms of U87 astrocytoma cell uptake and trafficking of monomeric versus protofibril Alzheimer's disease amyloid-β proteins.

Authors:  Yali Li; Deshu Cheng; Ran Cheng; Xinyu Zhu; Tao Wan; Jianmiao Liu; Rongying Zhang
Journal:  PLoS One       Date:  2014-06-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.